MEDİTERA

TIBBİ MALZEME SANAYİ VE TİCARET A.Ş.







2026 – 9M FINANCIAL RESULTS

Meditera Tıbbi Malzeme Sanayi ve Ticaret A.Ş. ("Meditera" or the "Company") announced its 2026 first nine months results today.

Meditera registered TL 2,233 M revenues and TL 320 M EBITDA in the first nine months of 2026. Thanks to cost-reduction measures, the EBITDA margin stood at 14.3% (9M 2025: 11.1%).



Details on Company's financial and operational data data are provided below.

TL M	9M 2026	9M 2025	% Δ
Revenues	**2.233**	**2.592**	**(14%)**
Domestic Sales	703	961	(27%)
International Sales	1,531	1.632	(6%)
Gross Profit	795	819	(3%)
EBITDA	**320**	**288**	**11%**
Net Profit	(72)	(103)	n.m.
Gross Profit Margin (%)	35.6%	31.6%	4.0 pp
EBITDA Margin (%)	**14.3%**	**11.1%**	3.2 pp
Net Profit Margin (%)	(3.2%)	(4.0%)	n.m.

TL M	9M 2026	2025	% Δ
Cash & Cash Equivalents	548	480	14%
Net Cash	523	432	21%

FINANCIAL RESULTS

All data presented in the financial results part have been adjusted for inflation in accordance with TAS 29 "Financial Reporting in Hyperinflationary Economies".

The Company's sales revenues decreased 14% in the first nine months of 2026 compared to the first nine months of 2025. The share of the export revenues in total revenues was 69% in the first nine months of 2026 (9M 2025: 63%).

In the first nine months of 2026, EBITDA increased by 11% year on year to TL 320 M. Despite the impact of inflationary pressures on costs and the adverse effects of rising oil prices on operating expenses, the cost-cutting measures implemented by the Company supported the improvement in the EBITDA margin. Furthermore, as previously indicated, the gradual easing of the pressure on profitability arising from the salary increases implemented at the beginning of the year, which particularly affected first-quarter profitability, also contributed positively to operating profitability in subsequent quarters. As a result of these developments, the Company recorded an EBITDA margin of 14.3% for the first nine months of 2026.

The new factory investment of our Company, located within our production campus in Tire and comprising 13,140 m² of indoor space, has been commissioned and production activities are ongoing. With this investment, our cleanroom area has nearly doubled, while our production capacity has also increased. In addition, the size of our R&D center has been expanded to 793 m², further strengthening our product development capabilities.

The contribution of the product groups whose production has commenced at our new facility to sales revenue is expected to increase gradually. As previously stated, due to the time required for licensing, authorization and certification processes applicable in the healthcare sector, the commercial contribution of these new products is realized progressively. Our new products used in anesthesia, intensive care and home care are expected to broaden our existing product portfolio and support our value-added sales. Necessary disclosures will be made to the public upon completion of the certification processes for the final products.

In addition, our rooftop solar power plant investments at our production facility located in the Tire Organized Industrial Zone have reached a total installed capacity of 2,389.80 kWp across an area of 10,330 m². In line with our strategy to expand our renewable energy investments, we have decided to make an additional investment in a new solar power plant with an installed capacity of 341.61 kWp, covering an area of approximately 2,050 m². Upon commissioning of this investment, which is planned for the fourth quarter of 2026, our total installed solar power capacity is expected to reach 2,731.41 kWp, with the total panel installation area increasing to 12,380 m². Through these investments, we aim to increase the proportion of our production facility's electricity needs met by renewable energy sources, reduce energy costs, enhance operational efficiency and profitability, and contribute to our environmental sustainability goals by reducing our carbon footprint.

Our company maintained its net cash position as of 30.09.2026 and recorded a net cash balance of TL 523 M, primarily driven by cash generated from its operations.

Based on the operating results of 2025, in line with the Board of Directors' resolution dated 06.03.2026, a gross cash dividend distribution proposal amounting to TRY 40.5 million, corresponding to 28.93% of the issued share capital, was prepared. Said proposal was approved at the Ordinary General Assembly Meeting held on 02.04.2026.

Throughout 2026, we continued our sales activities in both domestic and export markets while closely monitoring public and private sector tenders and new business opportunities. In this context, our Company was awarded the tender held by the Tekirdağ Provincial Health Directorate for chemotherapy drug preparation and administration services, with a bid amount of TL 19 million. We remain committed to maintaining a balance between cash flow management, profitability, operational efficiency and sustainable growth.

Looking ahead, our objective is to strengthen our position in international markets through our innovative product portfolio, expanding production capacity and strong export potential. In this regard, supported by our inclusion in the TURQUALITY Brand Support Program administered by the Republic of Türkiye Ministry of Trade, we aim to enhance our global brand recognition, expand our export network and create sustainable value for our shareholders.



ABOUT MEDİTERA

The first establishment of our company was founded in 1983 by Atilla Sevinçli, who is a pharmacits, in Izmir in 1983 and took its place among the leading medical equipment companies in the sector in the 90s.

Meditera is specialized in the production of anesthesia and intensive care breathing circuits, installation, operation and project design of oncology medicine preparation and implementation systems, distributorship, production and technical service of infusion pumps and sets as well as biocidal product production.

In addition, S & Mohr, 20% subsidiary of the Company established as a joint venture with Internacional Farmacéutica S.A. de C.V. (IFSA), manufactures surgical sutures in its facilities in Turkey and S&Mohr America, 60% subsidiary of the Company, manufactures respiratory circuits and accessories in its facilities in Mexico.

On the back of its high quality approach, our company produces for well-known global brands and exports to more than 100 customers in more than 80 countries under the Altech brand.

As of September 30, 2026, Meditera registered TL 2,233 M sales revenues and TL 4,254 M assets. The company's shares have been traded on Borsa Istanbul under the ticker "MEDTR" since July 2021. For more information, please contact https://www.meditera.com.tr/ or contact the Investor Relations Department.

For further information

Meditera Investor Relations

Tel: +90 232 237 59 49

E-mail: yatirimci@meditera.com.tr